| abstract |
The present invention provides a method of treating a patient having an autoimmune disease using an IL-17 antagonist, eg, an IL-17 antibody, eg, secukinumab, eg, psoriatic arthritis (PsA) or axial spondyloarthritis (axSpA). ), for example, non-radiological axial spondyloarthritis (nr-axSpA) or ankylosing spondylitis (AS). Also disclosed herein are methods of inhibiting the progression of structural damage in PsA and axSpA patients using an IL-17 antagonist, eg, an IL-17 antibody, such as secukinumab. The present invention also provides medicaments, pharmaceutical formulations, dosage forms, and kits for use in the disclosed methods. |